Additional file 1 of Long noncoding RNA MIR31HG and its splice variants regulate proliferation and migration: prognostic implications for muscle invasive bladder cancer

Additional file 1: Fig. S1. Expression of MIR31HG in BLCA tissue samples and cell lines based on in silico data. (A) Expression of MIR31HG was higher in basal (median expression 7.10 with range of 0 to 9.96) subtype than in luminal (median expression 5.21 with range of 0 to 10.16) and infiltrated (median expression 4.99 with range of 0 to 9.16) subtypes in patients of the TCGA cohort. (B) No significant difference of MIR31HG expression was found between lymph node metastasis negative and positive groups. (C) RNA-seq data from the Cancer Cell Line Encyclopedia showed expression levels in TPM (transcripts per million) for MIR31HG in 25 BLCA cell lines. Fig. S2. Kaplan-Meier plot of the TCGA cohort of OS and DFS associated with MIR31HG risk stratification. The group with high or low expression of MIR31HG showed no significant correlation with OS (A, median survival, 16 vs. 15 months, p = 0.9638) and DFS (B, median survival, 15 vs. 17 months, p = 0.4175) in the whole TCGA cohort. The numbers below the figures showed the number of patients at risk in each group. Fig. S3. Kaplan-Meier plot of the TCGA cohort with basal subtype of overall survival associated with MIR31HG Exon1–2 (Junction 3) risk stratification. (A) The group with high Junction 3 expression showed worse OS than the group with low expression (median survival, 17 vs. 14 months, p = 0.0298). (B) No significant difference was observed in DFS between the group with high and low Junction 3 expression (median survival, 17 vs. 15 months, p = 0.5670). The numbers below the figures showed the number of patients at risk in each group. Fig. S4. Kaplan-Meier plot of the Mannheim cohort with basal subtype of OS and DFS associated with MIR31HG and its splice variants risk stratification. No significant correlation was found with OS (A, median survival 18 vs. 20 months) and DFS (B, median survival 17 vs. 15 months) in the group with full-length transcript of MIR31HG. No significant correlation was found with OS (C, median survival 15 vs. 18 months) and DFS (D, median survival 29 vs. 17 months) in the group with MIR31HGΔE1. The group with high MIR31HGΔE3 expression showed a worse OS (E, median survival 13 vs. 22 months) compared to the group with low expression, no significant correlation was found with DFS (F, median survival 15 vs. 36 months). The numbers below the figures showed the number of patients at risk in each group. Table S1. siRNAs used in this study. Table S2. Primers and probes used in this study.